Phar­mas­set co-founder jumps in­to Covid-19 fight, with a new com­pa­ny and $215 mil­lion to get there

For 7 years, Atea Phar­ma­ceu­ti­cals hummed along, an­oth­er biotech in a city full of them, fil­ing patents, qui­et­ly pick­ing up a few small fund­ing rounds for mol­e­cules tar­get­ing he­pati­tis, Dengue and RSV — some of the few in­fec­tious dis­eases that could still gen­er­ate in­vestor in­ter­est.

Then Covid-19 struck and now they’ve raised $215 mil­lion in a sin­gle round from over a dozen in­vestors, in­clud­ing Bain Cap­i­tal and RA Cap­i­tal. They’ll use it to launch a cross-coun­try Phase II tri­al test­ing their lead drug, AT-527, as the lat­est new an­tivi­ral to go up against the coro­n­avirus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER